© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Abeona Therapeutics Inc. (ABEO) stock surged +1.93%, trading at $5.27 on NASDAQ, up from the previous close of $5.17. The stock opened at $5.17, fluctuating between $5.16 and $5.42 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 03, 2026 | 5.17 | 5.42 | 5.16 | 5.27 | 963.27K |
| Feb 02, 2026 | 5.10 | 5.23 | 4.99 | 5.17 | 746.92K |
| Jan 30, 2026 | 5.03 | 5.16 | 4.98 | 5.09 | 665.11K |
| Jan 29, 2026 | 4.81 | 5.17 | 4.79 | 5.08 | 1.62M |
| Jan 28, 2026 | 5.09 | 5.10 | 4.78 | 4.83 | 2.08M |
| Jan 27, 2026 | 5.14 | 5.20 | 5.05 | 5.11 | 1.05M |
| Jan 26, 2026 | 5.11 | 5.27 | 5.00 | 5.19 | 1.01M |
| Jan 23, 2026 | 5.37 | 5.37 | 5.14 | 5.16 | 1.4M |
| Jan 22, 2026 | 5.31 | 5.41 | 5.23 | 5.36 | 1.36M |
| Jan 21, 2026 | 5.31 | 5.38 | 5.19 | 5.31 | 1.19M |
| Jan 20, 2026 | 5.20 | 5.36 | 5.05 | 5.31 | 1.39M |
| Jan 16, 2026 | 5.48 | 5.69 | 5.20 | 5.25 | 2.15M |
| Jan 15, 2026 | 5.20 | 5.51 | 5.10 | 5.45 | 1.61M |
| Jan 14, 2026 | 5.08 | 5.21 | 5.07 | 5.19 | 720.06K |
| Jan 13, 2026 | 5.09 | 5.15 | 5.00 | 5.09 | 761.6K |
| Jan 12, 2026 | 5.19 | 5.19 | 4.98 | 5.10 | 1.22M |
| Jan 09, 2026 | 5.10 | 5.34 | 5.10 | 5.19 | 1.35M |
| Jan 08, 2026 | 5.11 | 5.17 | 5.02 | 5.09 | 1.66M |
| Jan 07, 2026 | 5.17 | 5.31 | 5.11 | 5.22 | 1.11M |
| Jan 06, 2026 | 5.19 | 5.21 | 5.07 | 5.16 | 1.17M |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
| Employees | 136 |
| Beta | 1.12 |
| Sales or Revenue | $3.50M |
| 5Y Sales Change% | -0.896% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |